Proactive Investors - Run By Investors For Investors
Why invest in INS?

Demand for Instem’s SEND platform is soaring

In a January update, Instem said trading had been in-line with expectations, helped by a 500% rise in orders for its SEND platform
scientist in laboratory
OVERVIEW: INS The Big Picture
Instem develops software that aids the regulatory submission process for drug makers
  • Makes software that helps drug developers bring their products to market

  • Some huge firms use its technology

  • Profitable in first-half

  • Latest update showed 500% rise in SEND orders


What it does

Instem PLC (LON:INS) develops and sells software that aids data collection and the regulatory submission process for drug makers.

In short, its tech helps its customers to bring their products to market faster.

The AIM owns more than a dozen software applications, including its flagship SEND technology.

SEND stands for Standard for the Exchange of Nonclinical Data and is a protocol set up by the US Food and Drug Administration. It ensures that companies present data in a consistent format.

Among Instem’s other top products is Samarind – a software-as-a-service (SaaS) platform that enables companies to register and track their regulated products worldwide by maintaining a single integrated database, which is then used to update drugs watchdogs as products change over time.

The company, which is valued at £50mln, has over 500 clients, including some of the world’s biggest pharmas. Last summer, for example, an unnamed Fortune 500 giant signed a deal worth US$750,000 to use Samarind.


How it’s doing

Instem hasn’t released its full-year numbers for 2018 yet, but investors were treated to a nice trading update in January.

In that announcement, the company said trading had been in-line with expectations as orders for its SEND platform grew 500% year-over-year.

It added that all three areas of the business – data collection, regulatory solutions and informatics – made “positive contributions”, while profit margins also strengthened.

Customers are now shifting away from the software licence model to recurring, SaaS, which aids customer retention and allows users to incrementally build the list of services they buy.

Instem ended the year with £3.6mln in the bank, which will increase as delayed payments from a small number of large pharma customers are received.

This, the firm said, will return the company to “more normal working capital cycles”.


What the boss says

“Instem has invested significantly in the business in recent years and these results further illustrate such investment converting into profitable growth,” said chief executive Phil Reason.

“In addition to a host of new client wins, many existing clients have extended their use of Instem's products and services and, importantly, have transitioned to our SaaS solutions.

“The company looks forward to building on this momentum, particularly for SEND related services, where order backlog and future revenue visibility is continually improving.”

View full INS profile View Profile

Instem PLC Timeline

April 11 2019
April 01 2019

Related Articles

IoT graphic
March 01 2019
The company is an investor and operator of technology companies with innovative IoT, AI and Blockchain solutions
Phone with apps
July 03 2019
The company owns and operates a scalable B2B SaaS platform that allows users to distribute their mobile apps across multiple app stores such as Google Play
Internet address bar
July 13 2019
In a February trading update, the firm said it had delivered a “strong” performance in 2018 with revenues for the year expected to be around £42.5mln compared to £24.3mln the year before

© Proactive Investors 2019

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use